Organization Profile

You just read:

New paper indicates a potential fifty-percent reduction in cardiac events for prostate cancer patients with pre-existing cardiovascular disease when treated with FIRMAGON® (degarelix) compared to LHRH agonists

News provided by

Ferring Pharmaceuticals

Feb 11, 2014, 07:59 ET